(firstQuint)Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk.

 Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation.

 Patients without a matched donor received the best available treatment.

 All patients will be followed at least 36 months or until the end of the study.

.

 Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk@highlight

Comparison of survival in patients with or without a matched donor at 36 months